GlobeStar Therapeutics Corporation
GSTC
$0.00
$0.000.00%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 193.40K | 167.60K | 155.90K | 287.80K | 1.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 193.40K | 167.60K | 155.90K | 287.80K | 1.28M |
| Operating Income | -193.40K | -167.60K | -155.90K | -287.80K | -1.28M |
| Income Before Tax | -197.70K | -175.00K | -163.80K | -350.60K | -1.28M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -197.70K | -175.00K | -163.80K | -350.60K | -1.28M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -197.70K | -175.00K | -163.80K | -350.60K | -1.28M |
| EBIT | -193.40K | -167.60K | -155.90K | -287.80K | -1.28M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 1.21B | 1.13B | 1.00B | 937.63M | 843.52M |
| Average Diluted Shares Outstanding | 1.21B | 1.13B | 1.00B | 937.63M | 843.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |